Connect with us
Information

Australia
North America
World

Investing News NetworkYour trusted source for investing success

North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides
Button

Precious Metals
Battery Metals
Base Metals
Energy
Critical Minerals

lexaria bioscience

POPULAR ARTICLES

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Lexaria Announces New R&D Plans for 2026

Lexaria Announces New R&D Plans for 2026

Lexaria Announces Positive Final Results from Human Pilot Study #5

Lexaria Announces Positive Final Results from Human Pilot Study #5

LATEST ARTICLES

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

Lexaria Awarded Six Additional Patents

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Latest News

Kinvestor Mining & Energy 2026 Virtual Investor Conference Agenda Announced for March 26, 2026

Homeland Nickel Engages Investor Relations Consultant

Homerun Resources Inc. Announces Binding Distribution Agreement with Cristal Sand Group, Securing First Commercial Sales of High-Purity Industrial Silica Sand from Santa Maria Eterna

Brixton Metals Graduates To Trading On The OTCQX

Lahontan Closes Second Tranche of Private Placement for an Aggregate of $11.7M

Outlook Reports world

Precious Metals
- Gold
- Silver
Battery Metals
Energy
- Uranium
- Oil and Gas

Base Metals
Critical Metals
- Rare Earths
Industrial Metals
Agriculture

- Cleantech
- Emerging Tech

- Biotech
- Cannabis

- Psychedelics
- Pharmaceuticals

Featured Stocks

Precipitate Gold

Precipitate Gold (PRG:CC)

PRG:CC

Uranium American Resources

UARI

Nuvau Minerals

Nuvau Minerals (NMC:CC)

NMC:CC

Mayfair Gold Corp.

Mayfair Gold Corp. (MFG:CC)

MFG:CC

Canada One Mining

Canada One Mining (CONE:CC)

CONE:CC

Generation Uranium

Generation Uranium (GEN:CC)

GEN:CC

More featured stocks

Browse Companies

Precious Metals
Battery Metals
Energy

Base Metals
Critical Metals

MARKETS

COMMODITIES

CURRENCIES